Koh Okamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Koh Okamoto has a total of 300 co-authors. Here are the top co-authors by number of shared publications:
Kyoji Moriya
Department of Infectious Diseases, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 Japan
18 shared publications- Sohei Harada
Department of Microbiology and Infectious Diseases, Toho University School of Medicine
14 shared publications Shu Okugawa
Department of Infectious Diseases, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 Japan
13 shared publicationsMahoko Ikeda
Department of Infectious Diseases, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 Japan
10 shared publications- Shu Okugawa
Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan
10 shared publications Marie Yamashita
Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan
9 shared publications
Latest Publications
- 21 August 2026
- Published by Elsevier in Transplantation Proceedings
- Vol. 58 (8) , 1557-1561
Significance of Nontuberculous Mycobacteria Detection in Liver Transplant Recipients: A Descriptive Epidemiology
- 21 August 2026
- Published by Elsevier in Transplantation Proceedings
- Vol. 58 (8) , 1557-1561
Significance of Nontuberculous Mycobacteria Detection in Liver Transplant Recipients: A Descriptive Epidemiology
- Open Access
- 7 August 2026
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 29 (3) , 53
Hepatitis A vaccination during ventricular assist device support in heart transplant candidates: immunogenicity and safety in a single-center cohort
Vaccination is among the cornerstones of infectious disease prevention in heart transplant candidates and recipients. Guidelines recommend an inactivated hepatitis A virus vaccine for heart transplant candidates, many of whom are on ventricular assist devices and at risk of hepatitis A virus exposure. However, data on the immunogenicity and safety of hepatitis A virus vaccines in these patients are lacking.This retrospective, observational, single-center study was conducted at our outpatient clinic between December 2019 and December 2025. The study participants were heart transplant candidates with ventricular assist devices aged ≥16 years who tested negative for anti-hepatitis A virus immunoglobulin G at baseline and completed the inactivated hepatitis A virus vaccination series. Anti-hepatitis A virus immunoglobulin G titers were measured after vaccination using a chemiluminescent immunoassay. Thirty-five individuals were included in the study. Immunosuppressive agents were used in four patients (11.4%). All participants achieved seroconversion at a median of 1 month after vaccination. The reverse cumulative distribution of the Anti-hepatitis A virus immunoglobulin G sample/cutoff values indicated that an adequate antibody response was achieved in individuals with ventricular assist devices. Adverse events of the vaccine were minor; two patients (6%) experienced local pain, and two (6%) subcutaneous hemorrhage. Seroconversion in patients with ventricular assist devices was high. hepatitis A virus vaccination should be completed before transplantation in heart transplant candidates, if indicated.
- 7 August 2026
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 29 (3) , 53
Open AccessHepatitis A vaccination during ventricular assist device support in heart transplant candidates: immunogenicity and safety in a single-center cohort
Vaccination is among the cornerstones of infectious disease prevention in heart transplant candidates and recipients. Guidelines recommend an inactivated hepatitis A virus vaccine for heart transplant candidates, many of whom are on ventricular assist devices and at risk of hepatitis A virus exposure. However, data on the immunogenicity and safety of hepatitis A virus vaccines in these patients are lacking.This retrospective, observational, single-center study was conducted at our outpatient clinic between December 2019 and December 2025. The study participants were heart transplant candidates with ventricular assist devices aged ≥16 years who tested negative for anti-hepatitis A virus immunoglobulin G at baseline and completed the inactivated hepatitis A virus vaccination series. Anti-hepatitis A virus immunoglobulin G titers were measured after vaccination using a chemiluminescent immunoassay. Thirty-five individuals were included in the study. Immunosuppressive agents were used in four patients (11.4%). All participants achieved seroconversion at a median of 1 month after vaccination. The reverse cumulative distribution of the Anti-hepatitis A virus immunoglobulin G sample/cutoff values indicated that an adequate antibody response was achieved in individuals with ventricular assist devices. Adverse events of the vaccine were minor; two patients (6%) experienced local pain, and two (6%) subcutaneous hemorrhage. Seroconversion in patients with ventricular assist devices was high. hepatitis A virus vaccination should be completed before transplantation in heart transplant candidates, if indicated.
- Open Access
- 17 July 2026
- Published by JMIR Publications Inc. in JMIR AI
- Vol. 5, e89750
Current Landscape of Generative AI Use as a Search Engine Among Resident Physicians: Cross-Sectional Study
Background: Acquiring generative AI (GenAI) literacy and avoiding knowledge collapse and inadequate skill development are critical for resident physicians in the GenAI era, who are highly susceptible to its influence, including those who are current nonusers. Objective: This study examined the degree of GenAI use as a search engine in clinical practice among resident physicians and compared differences in AI literacy and bedside behaviors in the management of infectious diseases between GenAI users and nonusers. Methods: This cross-sectional study was conducted through an original questionnaire survey administered in January 2025 to participants of the General Medicine In-Training Examination (GM-ITE), a nationwide computer-based test for postgraduate year 1 and year 2 resident physicians in Japan. The survey items covered the degree of GenAI use, GenAI literacy, and perceived bedside behaviors. In addition to the GM-ITE score, we collected data on demographics and survey responses. Statistical analysis was performed to compare attitudes toward GenAI use between GenAI users and nonusers. Additionally, the difference in their bedside behaviors in infectious disease management was assessed, adjusted for demographics, the learning environment, and GM-ITE score. Results: Of 9179 GM-ITE examinees, 2989 (32.6%) resident physicians from 546 hospitals completed the survey. Subsequent analyses were performed in 2850 respondents who answered the question regarding GenAI use as a search engine in clinical work. A total of 1124 (39.4%) participants reported using GenAI as a search engine, while 1726 (60.6%) were nonusers. Only 13% (144/1110) of users relied on it as a primary reference for differential diagnoses. Compared with nonusers, users were more likely to understand limitations such as confabulation (817/1103, 74.1% vs 991/1696, 58.4%; P <.001) and to recognize competencies essential for future physicians in infectious disease management, including history taking and physical examination (965/1106, 87.3% vs 1296/1706, 76%; P <.001). Ethical considerations were less commonly addressed overall, with 47.3% (1311/2770) examining fairness and 49.8% (1381/2774) examining transparency. Awareness was greater among users than nonusers (615/1092, 56.3% vs 696/1678, 41.5%; P <.001 for fairness and 645/1095, 58.9% vs 736/1679, 43.8%; P <.001 for transparency). GenAI use was independently associated with perceived favorable behaviors, such as thorough examination (adjusted odds ratio [aOR] 1.42, 95% CI 1.18‐1.70) and appropriate antimicrobial use (aOR 1.57, 95% CI 1.32‐1.87). Conclusions: Although GenAI use was not associated with self-reported behaviors indicative of knowledge collapse at this stage, GenAI literacy among resident physicians in Japan remains limited, particularly among nonusers. Given its rapid expansion, education on GenAI in clinical practice may be necessary for both users and nonusers, emphasizing critical thinking and ethical considerations, including transparency, in patient care.
- 17 July 2026
- Published by JMIR Publications Inc. in JMIR AI
- Vol. 5, e89750
Open AccessCurrent Landscape of Generative AI Use as a Search Engine Among Resident Physicians: Cross-Sectional Study
Background: Acquiring generative AI (GenAI) literacy and avoiding knowledge collapse and inadequate skill development are critical for resident physicians in the GenAI era, who are highly susceptible to its influence, including those who are current nonusers. Objective: This study examined the degree of GenAI use as a search engine in clinical practice among resident physicians and compared differences in AI literacy and bedside behaviors in the management of infectious diseases between GenAI users and nonusers. Methods: This cross-sectional study was conducted through an original questionnaire survey administered in January 2025 to participants of the General Medicine In-Training Examination (GM-ITE), a nationwide computer-based test for postgraduate year 1 and year 2 resident physicians in Japan. The survey items covered the degree of GenAI use, GenAI literacy, and perceived bedside behaviors. In addition to the GM-ITE score, we collected data on demographics and survey responses. Statistical analysis was performed to compare attitudes toward GenAI use between GenAI users and nonusers. Additionally, the difference in their bedside behaviors in infectious disease management was assessed, adjusted for demographics, the learning environment, and GM-ITE score. Results: Of 9179 GM-ITE examinees, 2989 (32.6%) resident physicians from 546 hospitals completed the survey. Subsequent analyses were performed in 2850 respondents who answered the question regarding GenAI use as a search engine in clinical work. A total of 1124 (39.4%) participants reported using GenAI as a search engine, while 1726 (60.6%) were nonusers. Only 13% (144/1110) of users relied on it as a primary reference for differential diagnoses. Compared with nonusers, users were more likely to understand limitations such as confabulation (817/1103, 74.1% vs 991/1696, 58.4%; P <.001) and to recognize competencies essential for future physicians in infectious disease management, including history taking and physical examination (965/1106, 87.3% vs 1296/1706, 76%; P <.001). Ethical considerations were less commonly addressed overall, with 47.3% (1311/2770) examining fairness and 49.8% (1381/2774) examining transparency. Awareness was greater among users than nonusers (615/1092, 56.3% vs 696/1678, 41.5%; P <.001 for fairness and 645/1095, 58.9% vs 736/1679, 43.8%; P <.001 for transparency). GenAI use was independently associated with perceived favorable behaviors, such as thorough examination (adjusted odds ratio [aOR] 1.42, 95% CI 1.18‐1.70) and appropriate antimicrobial use (aOR 1.57, 95% CI 1.32‐1.87). Conclusions: Although GenAI use was not associated with self-reported behaviors indicative of knowledge collapse at this stage, GenAI literacy among resident physicians in Japan remains limited, particularly among nonusers. Given its rapid expansion, education on GenAI in clinical practice may be necessary for both users and nonusers, emphasizing critical thinking and ethical considerations, including transparency, in patient care.
- 14 July 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (9) , 103033
Blood culture collection practice prior to empiric piperacillin/tazobactam in patients requiring hospitalization: a potential target for antimicrobial stewardship from a single-center retrospective observational study
- 14 July 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (9) , 103033
Blood culture collection practice prior to empiric piperacillin/tazobactam in patients requiring hospitalization: a potential target for antimicrobial stewardship from a single-center retrospective observational study
- Open Access
- 7 July 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e205
Current status and challenges in the assessment of antibiotic allergy information in electronic health records: a retrospective observational study of perioperative patients
Background: Inappropriate antibiotic allergy labeling often leads to the unnecessary avoidance of first-line therapies. The present study aimed to evaluate the current status of antibiotic allergy documentation and its assessment in patients undergoing surgery for which cefazolin was the recommended first-line prophylaxis in a Japanese hospital. Methods: This retrospective observational study was conducted at a university hospital in Tokyo from 2021 to 2023; included patients with a history of antimicrobial allergy who underwent surgery for which cefazolin was recommended; and assessed patient demographics, details of the allergies in electronic health records (EHR), and perioperatively administered antimicrobial agents. Results: Of 2,402 eligible patients, 243 (10.1%) had a registered antimicrobial allergy. The drug classes most frequently recorded in the EHR were cephalosporins (25.0%) and penicillins (24.0%). Documentation of allergy assessments by a physician (9.0%) or specialist (7.0%) was rare. Although 51.9% of the labeled patients had received cefazolin, non-first-line agents had also been frequently administered. Notably, clindamycin had been administered to 30% of the cases and had been widely used even among patients with only a penicillin allergy label despite the low risk of cross-reactivity. Conclusions: Antibiotic allergy labels in the EHR were often incomplete, infrequently assessed, and associated with substantial avoidance of first-line prophylaxis. Redesigning the EHR format to allow allergies to be distinguished from adverse events while retaining the standard evaluation pathways is essential to optimizing perioperative antimicrobial stewardship.
- 7 July 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e205
Open AccessCurrent status and challenges in the assessment of antibiotic allergy information in electronic health records: a retrospective observational study of perioperative patients
Background: Inappropriate antibiotic allergy labeling often leads to the unnecessary avoidance of first-line therapies. The present study aimed to evaluate the current status of antibiotic allergy documentation and its assessment in patients undergoing surgery for which cefazolin was the recommended first-line prophylaxis in a Japanese hospital. Methods: This retrospective observational study was conducted at a university hospital in Tokyo from 2021 to 2023; included patients with a history of antimicrobial allergy who underwent surgery for which cefazolin was recommended; and assessed patient demographics, details of the allergies in electronic health records (EHR), and perioperatively administered antimicrobial agents. Results: Of 2,402 eligible patients, 243 (10.1%) had a registered antimicrobial allergy. The drug classes most frequently recorded in the EHR were cephalosporins (25.0%) and penicillins (24.0%). Documentation of allergy assessments by a physician (9.0%) or specialist (7.0%) was rare. Although 51.9% of the labeled patients had received cefazolin, non-first-line agents had also been frequently administered. Notably, clindamycin had been administered to 30% of the cases and had been widely used even among patients with only a penicillin allergy label despite the low risk of cross-reactivity. Conclusions: Antibiotic allergy labels in the EHR were often incomplete, infrequently assessed, and associated with substantial avoidance of first-line prophylaxis. Redesigning the EHR format to allow allergies to be distinguished from adverse events while retaining the standard evaluation pathways is essential to optimizing perioperative antimicrobial stewardship.
- Open Access
- 26 January 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1)
Fantastic stewards and where to find them: a descriptive study of the heterogeneous disparity in physician–pharmacist–nurse distribution among the infectious disease workforce
Background: Infectious disease (ID) care involves a diverse range of professionals, yet the shortage and geographical disparity of ID physicians, among other professionals, remain underexplored. This cross-sectional descriptive study aimed to elucidate the distribution of ID physicians, infection control (IC) pharmacists, and IC nurses in Japan, focusing on the interrelations among the ID workforce within medically relevant geographical units. Methods: Publicly available data from 335 secondary medical areas (SMAs) in Japan, with a population of 125 million, were analyzed. Workforce distribution was assessed using the Gini index to quantify inequalities and spatial clustering across the SMAs per capita, per hospital bed, and per unit area. χ2 test was used to assess the association of hospital characteristics with the presence of each professional. Findings: The research subjects were 1,729 ID physicians, 1,371 IC pharmacists, and 2,657 IC nurses, whose workplace data were available in Japan as of 2023. The Gini coefficients for the densities of ID physicians, IC pharmacists, and IC nurses per 100,000 people were 0.46, 0.34, and 0.28, respectively. The density of the ID workforce per unit area (1,000 km 2 ) showed a positive correlation ( > 0.8) with any combination of ID physicians, IC pharmacists, and IC nurses. A total of 186 SMAs (56%) had at least one member from each professional group and 13 (3.9%) lacked staff from all three. Conclusions: The substantial variation in ID workforce composition across SMAs suggests opportunities for both regional and national policy and identifies new avenues for improving access to ID care.
- 26 January 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1)
Open AccessFantastic stewards and where to find them: a descriptive study of the heterogeneous disparity in physician–pharmacist–nurse distribution among the infectious disease workforce
Background: Infectious disease (ID) care involves a diverse range of professionals, yet the shortage and geographical disparity of ID physicians, among other professionals, remain underexplored. This cross-sectional descriptive study aimed to elucidate the distribution of ID physicians, infection control (IC) pharmacists, and IC nurses in Japan, focusing on the interrelations among the ID workforce within medically relevant geographical units. Methods: Publicly available data from 335 secondary medical areas (SMAs) in Japan, with a population of 125 million, were analyzed. Workforce distribution was assessed using the Gini index to quantify inequalities and spatial clustering across the SMAs per capita, per hospital bed, and per unit area. χ2 test was used to assess the association of hospital characteristics with the presence of each professional. Findings: The research subjects were 1,729 ID physicians, 1,371 IC pharmacists, and 2,657 IC nurses, whose workplace data were available in Japan as of 2023. The Gini coefficients for the densities of ID physicians, IC pharmacists, and IC nurses per 100,000 people were 0.46, 0.34, and 0.28, respectively. The density of the ID workforce per unit area (1,000 km 2 ) showed a positive correlation ( > 0.8) with any combination of ID physicians, IC pharmacists, and IC nurses. A total of 186 SMAs (56%) had at least one member from each professional group and 13 (3.9%) lacked staff from all three. Conclusions: The substantial variation in ID workforce composition across SMAs suggests opportunities for both regional and national policy and identifies new avenues for improving access to ID care.
- Open Access
- 2 July 2025
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 7 (4) , dlaf130
Evaluating the effectiveness of low-dose oral switch therapy for uncomplicated streptococcal or enterococcal bloodstream infection: a retrospective cohort study
Background: Although oral switch therapy (OST) is increasingly recognized as a viable option for uncomplicated gram-positive bloodstream infections (GP-BSI), its optimal dosage remains unclear. In Japan, high-dose regimens of key oral antimicrobials, such as amoxicillin (1000 mg thrice daily) or levofloxacin (750 mg once daily), are not approved. This study investigated the effectiveness of low-dose OST for GP-BSI in a population with a low prevalence of obesity. Methods: This retrospective, single-centre study involved patients aged ≥18 years with monomicrobial, uncomplicated BSI caused by ampicillin- or amoxicillin-susceptible Streptococcus or Enterococcus species treated between 2010 and 2023. Patients eligible for OST were identified on day 5 of microbiologically active therapy. Demographic, clinical, laboratory, and microbiological data were analysed. Using overlap weighting, we compared 90-day all-cause mortality between OST and intravenous therapy (IVT) only groups. Results: A total of 172 patients (86 with OST and 86 with IVT only) were included. The median body mass index was 22.5 (interquartile range [IQR], 19.2–24.7), and the median duration of therapy was 14 days (IQR, 12–15 days). Common oral regimens included amoxicillin (n = 34, 39.5%), amoxicillin/clavulanate (n = 24, 27.9%), and levofloxacin (n = 12, 14.0%). No significant difference in 90-day all-cause mortality was observed between OST and IVT groups (odds ratio, 0.73; 95% confidence interval, 0.23–2.29). Conclusions: Low-dose OST may be effective for clinically stable patients with uncomplicated GP-BSI in settings with low obesity prevalence.
- 2 July 2025
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 7 (4) , dlaf130
Open AccessEvaluating the effectiveness of low-dose oral switch therapy for uncomplicated streptococcal or enterococcal bloodstream infection: a retrospective cohort study
Background: Although oral switch therapy (OST) is increasingly recognized as a viable option for uncomplicated gram-positive bloodstream infections (GP-BSI), its optimal dosage remains unclear. In Japan, high-dose regimens of key oral antimicrobials, such as amoxicillin (1000 mg thrice daily) or levofloxacin (750 mg once daily), are not approved. This study investigated the effectiveness of low-dose OST for GP-BSI in a population with a low prevalence of obesity. Methods: This retrospective, single-centre study involved patients aged ≥18 years with monomicrobial, uncomplicated BSI caused by ampicillin- or amoxicillin-susceptible Streptococcus or Enterococcus species treated between 2010 and 2023. Patients eligible for OST were identified on day 5 of microbiologically active therapy. Demographic, clinical, laboratory, and microbiological data were analysed. Using overlap weighting, we compared 90-day all-cause mortality between OST and intravenous therapy (IVT) only groups. Results: A total of 172 patients (86 with OST and 86 with IVT only) were included. The median body mass index was 22.5 (interquartile range [IQR], 19.2–24.7), and the median duration of therapy was 14 days (IQR, 12–15 days). Common oral regimens included amoxicillin (n = 34, 39.5%), amoxicillin/clavulanate (n = 24, 27.9%), and levofloxacin (n = 12, 14.0%). No significant difference in 90-day all-cause mortality was observed between OST and IVT groups (odds ratio, 0.73; 95% confidence interval, 0.23–2.29). Conclusions: Low-dose OST may be effective for clinically stable patients with uncomplicated GP-BSI in settings with low obesity prevalence.
- Open Access
- 2 July 2025
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 7 (4)
The effect of intraoperative excessive bleeding on the pharmacokinetics of ampicillin and sulbactam in recipients of living donor liver transplantation in Japan
Objective: Guidelines recommend redosing with intravenous prophylactic antibiotics when excessive bleeding exceeds 1500 mL during surgery based on the pharmacokinetics data of cefazolin. However, the necessity for redosing of other antibiotics and the threshold volume of blood loss necessitating such supplementation remain undefined. We investigated plasma antibiotic concentrations during liver transplant surgery in patients with frequent excessive bleeding. Methods: A single-centre, prospective, observational pharmacokinetic study was conducted. Adult liver transplant recipients who received 2 g of ampicillin and 1 g of sulbactam every 3 h during surgery were included. Blood samples were collected hourly during surgery, and intraoperative bleeding amounts were reviewed from anaesthesia records. Plasma concentrations of ampicillin and sulbactam were determined using validated liquid chromatography-tandem mass spectrometry. The probability of target attainment was set at 80% free time above the MIC (fT > MIC). Results: Twenty participants were included. Of these, 11 participants (55%) were female. The median age, body weight, and bleeding volume were 52 years, 62.1 kg, and 11 158 mL, respectively. The intraoperative clearance of ampicillin was 80.28 mL/min, and sulbactam was 77.23 mL/min. The fT > MIC for both ampicillin and sulbactam tended to be lower with bleeding > 20 000 mL than with less bleeding. Plasma concentrations of ampicillin and sulbactam were maintained during surgery without redosing, even after bleeding exceeded 1500 mL. Conclusions: Even with excessive bleeding, administering 3 g of ampicillin/sulbactam every 3 h maintained sufficient plasma concentration. Redosing may be unnecessary unless total bleeding exceeds 20 000 mL.
- 2 July 2025
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 7 (4)
Open AccessThe effect of intraoperative excessive bleeding on the pharmacokinetics of ampicillin and sulbactam in recipients of living donor liver transplantation in Japan
Objective: Guidelines recommend redosing with intravenous prophylactic antibiotics when excessive bleeding exceeds 1500 mL during surgery based on the pharmacokinetics data of cefazolin. However, the necessity for redosing of other antibiotics and the threshold volume of blood loss necessitating such supplementation remain undefined. We investigated plasma antibiotic concentrations during liver transplant surgery in patients with frequent excessive bleeding. Methods: A single-centre, prospective, observational pharmacokinetic study was conducted. Adult liver transplant recipients who received 2 g of ampicillin and 1 g of sulbactam every 3 h during surgery were included. Blood samples were collected hourly during surgery, and intraoperative bleeding amounts were reviewed from anaesthesia records. Plasma concentrations of ampicillin and sulbactam were determined using validated liquid chromatography-tandem mass spectrometry. The probability of target attainment was set at 80% free time above the MIC (fT > MIC). Results: Twenty participants were included. Of these, 11 participants (55%) were female. The median age, body weight, and bleeding volume were 52 years, 62.1 kg, and 11 158 mL, respectively. The intraoperative clearance of ampicillin was 80.28 mL/min, and sulbactam was 77.23 mL/min. The fT > MIC for both ampicillin and sulbactam tended to be lower with bleeding > 20 000 mL than with less bleeding. Plasma concentrations of ampicillin and sulbactam were maintained during surgery without redosing, even after bleeding exceeded 1500 mL. Conclusions: Even with excessive bleeding, administering 3 g of ampicillin/sulbactam every 3 h maintained sufficient plasma concentration. Redosing may be unnecessary unless total bleeding exceeds 20 000 mL.
- Open Access
- 7 June 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (6) , 437
Proposed Diagnostic Criteria for Invasive Pulmonary Aspergillosis in Patients with Autoimmune Inflammatory Rheumatic Diseases: A Proof-of-Concept Study
The EORTC/MSGERC definition lacks sufficient sensitivity for diagnosing invasive pulmonary aspergillosis (IPA) in patients with autoimmune inflammatory rheumatic diseases (AIIRDs). We hypothesized that the partial fulfillment of the EORTC/MSGERC definition can improve its diagnostic sensitivity. This retrospective observational study included patients with AIIRDs on immunosuppressive therapy who underwent serum galactomannan antigen testing for suspected IPA. Patients who fulfilled the clinical features or mycological evidence as per the EORTC/MSGERC definition were considered as having “potential IPA.” We compared the clinical characteristics of 364 patients who were categorized into 3 groups—potential IPA (n = 29), proven/probable IPA (n = 24), and non-IPA (n = 311; not meeting any definition). The potential and proven/probable IPA groups had significantly lower survival rates than the non-IPA group (p < 0.001). The potential IPA (adjusted hazard ratio [aHR], 2.0; 95% confidence interval [CI], 1.1–3.8) and proven/probable IPA (aHR, 2.6; 95% CI, 1.4–4.9) were independent risk factors for mortality. Compared with the EORTC/MSGERC definition, our proposed criteria improved sensitivity based on the diagnosis at the end of observation (50.0%, 100.0%, respectively). The characteristics and mortality rates of patients were similar between the potential and proven/probable IPA groups. Using these criteria for clinical diagnosis may provide high sensitivity.
- 7 June 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (6) , 437
Open AccessProposed Diagnostic Criteria for Invasive Pulmonary Aspergillosis in Patients with Autoimmune Inflammatory Rheumatic Diseases: A Proof-of-Concept Study
The EORTC/MSGERC definition lacks sufficient sensitivity for diagnosing invasive pulmonary aspergillosis (IPA) in patients with autoimmune inflammatory rheumatic diseases (AIIRDs). We hypothesized that the partial fulfillment of the EORTC/MSGERC definition can improve its diagnostic sensitivity. This retrospective observational study included patients with AIIRDs on immunosuppressive therapy who underwent serum galactomannan antigen testing for suspected IPA. Patients who fulfilled the clinical features or mycological evidence as per the EORTC/MSGERC definition were considered as having “potential IPA.” We compared the clinical characteristics of 364 patients who were categorized into 3 groups—potential IPA (n = 29), proven/probable IPA (n = 24), and non-IPA (n = 311; not meeting any definition). The potential and proven/probable IPA groups had significantly lower survival rates than the non-IPA group (p < 0.001). The potential IPA (adjusted hazard ratio [aHR], 2.0; 95% confidence interval [CI], 1.1–3.8) and proven/probable IPA (aHR, 2.6; 95% CI, 1.4–4.9) were independent risk factors for mortality. Compared with the EORTC/MSGERC definition, our proposed criteria improved sensitivity based on the diagnosis at the end of observation (50.0%, 100.0%, respectively). The characteristics and mortality rates of patients were similar between the potential and proven/probable IPA groups. Using these criteria for clinical diagnosis may provide high sensitivity.
- Open Access
- 12 March 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (4) , 1-10
Characteristics and management of systemic sclerosis-related osteomyelitis: a retrospective cohort study
Digital ulcers in patients with systemic sclerosis (SSc) can be complicated by SSc-related osteomyelitis (SRO). The microbiological data and optimal management of SRO remain unclear. This single-center retrospective study involved patients with SSc aged 18 or older from April 2005 to March 2022. Diagnosis of SRO was based on clinical presentation and MRI findings. The accuracy of the superficial swab culture results was estimated using the bone culture as a reference. Temporal changes in local signs for up to a year were collected, and their association with (1) duration of antimicrobial therapy (> 6 weeks) or (2) surgical interventions was assessed using univariable analyses. Among the 2,126 patients, 46 (2.2%) were diagnosed with SRO. In seven patients whose swab and bone cultures were both available, two (28.6%) had swab cultures identifying all the organisms detected in bone cultures. Resolution of local inflammatory signs consistently preceded wound closure. Three months after therapy initiation, prolonged antimicrobial therapy was not significantly associated with the resolution of local inflammatory signs (16/19 [84.2%] vs. 12/14 [85.7%]; P = 1.00), and surgical intervention was not significantly associated with wound dehiscence (6/9 [66.7%] vs. 20/24 [83.3%]; P = 0.36). Superficial swab cultures may not reliably reflect the true causative organism of SRO. Prolonging antimicrobial therapy beyond six weeks may be of little benefit for patients with SRO when local inflammatory signs improve. Surgical intervention may be a safe and effective option for selected patients with SRO.
- 12 March 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (4) , 1-10
Open AccessCharacteristics and management of systemic sclerosis-related osteomyelitis: a retrospective cohort study
Digital ulcers in patients with systemic sclerosis (SSc) can be complicated by SSc-related osteomyelitis (SRO). The microbiological data and optimal management of SRO remain unclear. This single-center retrospective study involved patients with SSc aged 18 or older from April 2005 to March 2022. Diagnosis of SRO was based on clinical presentation and MRI findings. The accuracy of the superficial swab culture results was estimated using the bone culture as a reference. Temporal changes in local signs for up to a year were collected, and their association with (1) duration of antimicrobial therapy (> 6 weeks) or (2) surgical interventions was assessed using univariable analyses. Among the 2,126 patients, 46 (2.2%) were diagnosed with SRO. In seven patients whose swab and bone cultures were both available, two (28.6%) had swab cultures identifying all the organisms detected in bone cultures. Resolution of local inflammatory signs consistently preceded wound closure. Three months after therapy initiation, prolonged antimicrobial therapy was not significantly associated with the resolution of local inflammatory signs (16/19 [84.2%] vs. 12/14 [85.7%]; P = 1.00), and surgical intervention was not significantly associated with wound dehiscence (6/9 [66.7%] vs. 20/24 [83.3%]; P = 0.36). Superficial swab cultures may not reliably reflect the true causative organism of SRO. Prolonging antimicrobial therapy beyond six weeks may be of little benefit for patients with SRO when local inflammatory signs improve. Surgical intervention may be a safe and effective option for selected patients with SRO.